Novel Perspectives in Hepato-Biliary and Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 2383
Special Issue Editors
Interests: HCC; ERCP; tumor ablation; prognosis; molecular markers
2. Department of General Surgery, University of Medicine and Pharmacy “Iuliu Hațieganu”, 400347 Cluj-Napoca, Romania
Interests: surgery; liver resection; DPC
Special Issue Information
Dear Colleagues,
Pancreatic and hepatobiliary tumors continue to rank among the deadliest cancers worldwide. Due to a low response rate to treatment, these tumors continue to have a high death rate, a poor prognosis and survival rate, and an overall poor patient outcome. The multimodal strategy currently used in treatment includes systemic therapy, radiation therapy, and surgery. The treatment of hepatobiliary pancreatic cancer is under investigation in a variety of fields.
The use of immunotherapy in hepatobiliary pancreatic tumors is crucial and presents a rapidly developing field of study in cancer treatment. The most recent developments in checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are among the immunotherapy areas used to treat hepatobiliary and pancreatic malignancies; their clinical effectiveness and potential to increase survival rates are being examined. Targeted therapy, which emphasizes molecularly targeted medicines and precision medicine techniques based on genetic profiling, is another option. These tactics have the ability to customize care for specific patients, improving therapeutic results and reducing side effects.
In recent years, increasingly more patients have become eligible for combination therapies, which combine immunotherapy and targeted therapy with more conventional forms of treatment. Such combinations' synergistic effects have demonstrated promise in overcoming resistance and improving the effectiveness of treatment. Additionally, advancements in robotics and less invasive surgical methods are enhancing surgical results and shortening patient recovery periods. With the advancement of methods like image-guided radiation therapy (IGRT) and stereotactic body radiotherapy (SBRT), radiation treatment continues to evolve. These developments provide patients with hepatobiliary pancreatic tumors fresh hope by increasing the accuracy and efficacy of radiation therapy. Furthermore, enhancing prognoses requires the discovery of novel biomarkers for early detection and therapy monitoring.
Preoperative biliary drainage represents another important pillar and has a direct impact on the perioperative prognosis of patients with obstructive jaundice and significantly compromised liver function due to hepato-bilio-pancreatic malignancies. The development of a variety of preoperative biliary methods, from endoscopic stenting to percutaneous drainage methods and even surgical diversion, constitutes another field of interest.
To enhance the current knowledge and highlight new trends in hepato-billiary and pancreatic cancer management, this Special Issue aims to gather the most recent studies and clinical insights on these cutting-edge approaches. Original research, reviews, systemic reviews, and mini-reviews are all welcome.
Dr. Tudor Mocan
Dr. Emil-Ioan Moiș
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HCC
- cholangiocarcinoma
- surgery
- biliary drainage
- pancreatic cancer
- combination therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
